MVA Mosaic HIV vaccine - Janssen Vaccines and Prevention

Drug Profile

MVA Mosaic HIV vaccine - Janssen Vaccines and Prevention

Alternative Names: Modified Vaccinia Ankara Mosaic HIV vaccine; MVA-Mosaic

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 24 Jul 2017 Immunogenecity and adverse events data from a phase I/II trial in HIV infections (Prevention) released by Johnson and Johnson
  • 01 Sep 2016 Phase-I/II clinical trials in HIV infections (Combination therapy, Treatment-experienced) in Thailand (IM) (NCT02919306)
  • 01 Nov 2015 Crucell Holland completes a phase I trial in HIV infections (Prevention) in USA (IM) (NCT02218125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top